2024 SITC IBCG Definitions, End Points, and Clinical Trial Designs for Bladder Cancer

Back to Library

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer & the International Bladder Cancer Group 

03-27-2024 11:42

The Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) hosted the Definitions, End Points, and Clinical Trial Designs for Bladder Cancer webinar, a collaborative cancer immunotherapy education program live streamed on March 18, 2024.

Moderators

  • Matthew D. Galsky, MD – Mount Sinai
  • Ashish Kamat, MD, MBBS – University of Texas MD Anderson Cancer Center

Faculty

  • Andrea Apolo, MD — National Cancer Institute/Center for Cancer Research
  • Shilpa Gupta, MD — Cleveland Clinic Taussig Cancer Institute
  • Seth Lerner, MD, FACS — Baylor College of Medicine
  • Sarah P. Psutka, MD, MS — University of Washington

Program Background

On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the “Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group,” in the Journal of Clinical Oncology. These recommendations provide a detailed clinical trial design guide to maximize the chance of capturing the benefit of medical therapies for each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer (NMIBC) to metastatic disease.

SITC and IBCG formed a partnership to develop Expert Panel recommendations in response to a significant unmet need that still exists for standardized trials designed for new urothelial carcinoma (UC) treatments specific to stage and treatment approach. In this new manuscript, the Expert Panel discusses standardization of key clinical design elements to identify optimal treatment options and improve outcomes for patients. By providing standardized criteria, the paper also aims to benefit the field by allowing cancer researchers to develop more comparable and robust data sets for meta-analyses. 

Learning Objectives

  1. Understand appropriate definitions and end points that are relevant to the understanding of existing trials in each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer (NMIBC) to metastatic disease.
  2. Understand nuances of rationally selected endpoints, eligibility criteria, response measurement, statistical analyses (including minimal value for effect and sample size considerations), and pathology considerations
  3. Apply these key clinical design elements and standardized criteria to their clinical trials (and practice) to identify optimal treatment options and improve outcomes for patients.
  4. Apply these criteria to develop comparable and robust data sets for meta-analyses. 

Click here to view the manuscript and full program details for the Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer & the International Bladder Cancer Group.

Statistics
0 Favorited
11 Views
8 Files
0 Shares
1 Downloads

You Must Be Logged In To Access This Resource

This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.

With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.

Tags and Keywords

Related Entries and Links

No Related Resource entered.